Osborn Office
7337 E. 2nd St.

Scottsdale, Arizona 85251

(480) 922-4600

10460 N. 92nd St.

Scottsdale, Arizona 85258

(480) 922-4600

19646 N. 27th Ave. Suite 108

Phoenix, Arizona 85027

(480) 922-4600

3645 S. Rome Street Ste. 116

Gilbert, Arizona 85297

(480) 922-4600
This page can be revisited at:


When an early state breast cancer tumor is surgically removed by lumpectomy, physicians usually recommend a course of radiotherapy to minimize the chances of cancer recurrence. Radiation therapy is used to effectively "sterilize" any residual cancerous or pre-cancerous microscopic tissue that may exist in the vicinity of the tumor. Radiation therapy is an indispensable part of the breast conservation therapy procedure.
Radiation of the breast tissue can be performed by different techniques. The established standard-of-care for breast radiotherapy is whole breast irradiation (WBI). This is a procedure that is performed daily for a period of 6-7 weeks after surgery. An important part of the WBI process is the delivery of a higher localized dose, known as the "boost dose," to the lumpectomy cavity margin - the most likely site for cancer recurrence. AccuBoost is designed to target and deliver the all-important boost dose accurately and reliably.
For women having whole breast irradiation, the surgical cavity is boosted to a slightly higher dose. The boost usually takes 5-8 treatments given daily. A small field is mapped out around the surgical cavity.
Using Ultrasound
The boost field is then defined by Ultrasound images. Electrons are used to deliver the radiation so that they will no penetrate too deep into the underlying chest wall or lungs.
The AccuBoost system is designed to take the guess work out of "daily patient positioning" and "dose targeting" for the boost phase of the procedure. By using real-time image guided radiation therapy (IGRT), the AccuBoost system provides a simple, accurate method for accurate boost dose targeting. Furthermore, by sharing the same platform for imaging (by IGRT) and applicator positioning, the AccuBoost system targets the dose precisely to where it needs to go and minimizes side effects of radiation.
Clinical Trials
The boost field is easy to locate and treat without any exiting dose to lungs or ribs. As the company states, "you see what you treat and treat what you see." This is a very exciting new technique providing yet another option for women!
As these breast cancer treatment results matured, and the previously mentioned national phase II clinical trial run by the Radiation Therapy Oncology Group (RTOG) and sponsored by the National Cancer Institute was successfully completed, momentum and support for brachytherapy spiraled upward.
The RTOG 95-17 results have been peer-reviewed and published in an international medical journal in 1998 by Drs. Arthur, Kuske, and others. Currently a national phase III clinical trial (NSABP B-39/RTOG 0413) is on-going, and directly compares 6 weeks of whole breast irradiation with 5 days of partial breast irradiation. Over 3000 patients have heroically signed-up for this trial, with a planned total of 4300 patients to be enrolled by 2011. Dr. Kuske has been privileged to play a major role in the design and leadership of this trial, and Dr. Kuske, Dr. Quiet and the women of Arizona have been the leading participants out of over 250 institutions! We have enrolled more women onto phase III breast cancer trials than the radiation departments of Harvard, Memorial Sloan Kettering, and MD Anderson combined!